Investigation on the Efficacy of WO 2085 Moisturising Cream for Breast Cancer Patients Suffering From Vulvovaginal Dryness

Multicentric Study on the Application of WO 2085 Moisturising Cream for Breast Cancer Patients Suffering From the Symptoms of Vulvovaginal Dryness

The aim of the study is to gain further experience with regard to the performance of the medical device WO2085 Moisturising Cream for breast cancer patients undergoing chemotherapy or treatment with anti-oestrogens / aromatase inhibitors

The goal of this application study was to answer the question as to whether the application of WO2085 Moisturising Cream for breast cancer patients undergoing chemotherapy or treatment with anti-oestrogens / aromatase inhibitors can result in an improvement in the subjective symptoms and objective diagnoses of vulvovaginal dryness while also ensuring good tolerability.

Inclusion Criteria:

• Women with breast cancer undergoing chemotherapy OR therapy with aromatase inhibitors or anti-oestrogens (either at present or up to 3 months after ending treatment) AND with symptoms of vulvovaginal dryness since the start of tumour treatment
• Written declaration of consent for the voluntary participation in the study is present

Exclusion Criteria:

• Women who suffered symptoms of vulvovaginal dryness prior to the start of tumour treatment
• Patients undergoing radiation therapy
• Patients with other tumours
• A current vaginal infection
• Medical conditions related to the vulva or vagina
• Current additional therapy of vulvovaginal dryness or vulvovaginal atrophy
• Women who are not able to participate properly in this study
• Current alcohol and/or drug abuse
• Pregnant or lactating women